AJANTPHARM2020-01-012020-03-31in-bse-fin:OneOperatingExpenses01Member AJANTPHARM2020-01-012020-03-31in-bse-fin:FourOperatingExpenses01Member iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares AJANTPHARM 2019-04-01 2020-03-31 2020-05-11 INR Crores Yearly Single segment PHARMACEUTICAL 2020-01-01 2020-03-31 Audited Standalone 5606800000.00 541000000.00 6147800000.00 1722900000.00 229900000.00 -243400000.00 1172600000.00 29300000.00 248900000.00 1666300000.00 4826500000.00 1321300000.00 -25100000.00 1296200000.00 424900000.00 -13800000.00 411100000.00 0.00 885100000.00 0.00 0.00 0.00 0.00 885100000.00 -3200000.00 881900000.00 881900000.00 0.00 175400000.00 2 10.14 10.14 0.00 0.00 10.14 10.14 1. The above standalone results have been reviewed by Audit Committee and approved by the Board of Directors at their meeting held on 20 May 2020. The statutory auditors have expressed unmodified opinion. The audit report has been filed with the stock exchange and is available on company website. n n2. The figures for the quarter ended 31 March 2020 and 31 March 2019 are the balancing figures between audited figures in respect of full financial year and the unaudited published year to date figure upto the third quarter ended 31 December 2019 and 31 December 2018 respectively. n n4. During the year 7,500 (previous year 8,500) equity shares of Rs. 2 each, fully paid up, were allotted upon exercise of vested options pursuant to the Employees Stock Options Scheme, 2011, resulting in an increase in the paid-up share capital by Rs. 15,000 (previous year Rs. 17,000) and securities premium by Rs. 0.93 crores (previous year Rs.1.20 crores). n n5. The Company has adopted the modified retrospective approach as per Ind AS 116 - Leases to account for its leases, effective from reporting periods beginning 1 April 2019. This has resulted in recognising right of use assets of Rs. 28.14 crores and a corresponding lease liability of Rs. 31.95 crores by adjusting retained earnings by Rs. 3.81 crores and also recognising right of use of asset of Rs. 71.30 crores related to leasehold land as at 1 April 2019. In the statement of profit and loss for the current period, operating lease expenses has changed from rent to depreciation cost for the right of use assets and finance cost for interest accrued on lease liability. To this extent, performance for the current period ended 31 March 2020 is not comparable with previous period results. n n6. The Company operates exclusively in one reportable business segment i.e., Pharmaceuticals . n n7. Pursuant to a fire incident on 31 August 2019 at Guwahati plant, certain property, plant and equipment and inventory were damaged. The Company has lodged insurance claim and the loss after adjusting insurance claim receivable has been presented under exceptional item in the financial result. Single segment 2019-04-01 2020-03-31 Unaudited Standalone 21964200000.00 1842000000.00 23806200000.00 5562200000.00 987300000.00 90200000.00 4378200000.00 91000000.00 912900000.00 5618500000.00 17640300000.00 6165900000.00 -39200000.00 6126700000.00 1680900000.00 34500000.00 1715400000.00 0.00 4411300000.00 0.00 0.00 0.00 0.00 4411300000.00 -25500000.00 4385800000.00 4385800000.00 0.00 175400000.00 2 24437600000.00 50.55 50.55 0.00 0.00 50.55 50.55 Other Expenses 1666300000.00 Other Expenses 5618500000.00